Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Martin G. Pomper

Martin G. Pomper

Department Affiliation: Primary:  Radiology;
Secondary: Oncology; Radiation Oncology; Environmental Health Sciences; Pharmacology and Molecular Sciences; Psychiatry; Pathobiology
Degree: M.D., Ph.D., University of Illinois at Urbana-Champaign
Rank: William R. Brody Professor of Radiology
Telephone Number: 410-955-2789
Fax Number: 443-817-0990
E-mail address: mpomper@jhmi.edu
School of Medicine Address: Cancer Research Bldg. 2, Room 492, 1550 Orleans Street, Baltimore, MD 21231 

Translational Molecular Imaging

Recent advances in molecular and cellular biology, the emergence of more sophisticated animal models of human disease and the development of sensitive, high-resolution imaging systems enable the study of pathophysiology noninvasively in unprecedented detail.  The overall goal of our work is to develop new techniques and agents to study human disease through imaging.  We concentrate on two areas, i.e., cancer and central nervous system processes.  Our work extends from basic chemical and radiochemical synthesis to clinical translation.

Current synthetically oriented projects include the development of radiopharmaceuticals for positron emission tomography (PET) and single photon emission computed tomography (SPECT) as well as optical imaging agents to be used for surgical guidance and nanomedicines.  Such agents typically bind receptors or enzymes.  One major effort involves developing a series of urea derivatives that have a high affinity for the prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II, as leads for imaging agents for prostate cancer and psychiatric disease.  Several of those agents are in clinical trials.  We have recently embarked on a program to develop radioimmunodiagnostic and low molecular weight imaging agents for chemokine receptors, and have developed a general technique for molecular-genetic imaging and therapy of cancer. 

Human PET studies are also a priority, and we have several protocols for studying neurotransmission and inflammation in a variety of central nervous system pathologies including AIDS dementia and traumatic brain injury.  We have also developed new methods to image infection and to image and treat virs-associated tumors - both of which are in clinical trials underway at Johns Hopkins and elsewhere. 

Representative Publications:  

  • Kim, T.H., Swierczewska, M., Oh, Y., Kim, A., Jo, D.G., Park, J.H., Byun, Y., Sadegh-Nasseri, S., Pomper, M.G., Lee, K.C., Lee, S. Mix to validate: A facile, reversible PEGylation for fast screening of potential therapeutic proteins in vivo. Angew. Chem. Int. Edit. 52:6880-4, 2013. Pub Med Reference
     
  • Yang, X., Song, X., Li, Y., Liu, G., Banerjee, S.R., Pomper, M.G., McMahon, M.T. Salicylic acid and analogues as diaCEST MRI contrast agents with highly shifted exchangeable proton frequencies. Angew. Chem. Int. Edit. 52:8116-9, 2013. Pub Med Reference
     
  • Banerjee, S.R., Pullambhatla, M., Foss, C.A., Falk, A., Byun, Y., Nimmagadda, S., Mease, R.C., Pomper, M.G. Effect of chelators on the pharmacokinetics of 99mTc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). J. Med. Chem. 2013 Jul 22. Pub Med Reference
     
  • Cho, S.Y., Gage, K.L., Mease, R.C., Senthamizhchelvan, S., Holt, D.P., Jeffrey-Kwanisai, A., Endres, C.J., Dannals, R.F., Sgouros, G., Lodge, M., Eisenberger, M.A., Rodriguez, R., Carducci, M.A., Rojas, C., Slusher, B.S., Kozikowski, A.P., Pomper, M.G. Biodistribution, tumor detection and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen in patients with metastatic prostate cancer. J. Nucl. Med. 53:1883-91, 2012. Pub Med Reference
     
  • Banerjee, S.R., Pullambhatla, M., Byun, Y., Nimmagadda, S., Foss, C.A., Green, G., Fox, J.J., Lupold, S.E., Mease, R.C., Pomper, M.G. Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen.  Angew. Chem. Int. Edit. 50:9167-70, 2011. Pub Med Reference
     
  • Bhang, H.-E., Gabrielson, K.L., Laterra, J., Fisher, P.B., Pomper, M.G.  Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression.  Nat. Med. 17:123-129, 2011. Pub Med Reference
     
  • Nimmagadda, S., Pullambhatla, M., Stone, K., Green, G., Bhujwalla, Z.M., Pomper, M.G.  Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography.  Cancer Res. 70(10):3935-44, 2010. Pub Med Reference
     
  • Zhang, Y., Byun, Y., Ren, Y.R., Liu, J.O., Laterra, J., Pomper, M.G.  Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.  Cancer Res. 69:5867-75, 2009. Pub Med Reference
     
  • Fu, D,, Tanhehco, Y., Chen, J., Foss, C.A., Fox, J.J., Chong, J.-M., Fukayama, M., Sgouros, G., Kowalski, J., Pomper, M.G., Ambinder, R.F.  Bortezomib-induced enzyme-targeted radiotherapy in herpesvirus-associated tumors.  Nat. Med. 14:1118-1122, 2008.  Pub Med Reference
     
  • Zhou, J., Neale, J.H., Pomper, M.G., Kozikowski, A.P.  NAAG peptidase inhibitors and their potential for diagnosis and therapy.  Nat. Rev. Drug Discovery  4:1015-26, 2005. Pub Med Reference
     
  • Bettegowda, C., Foss, C.A., Wang, Y., Fox, J., Zhou, S., Kinzler, K., Vogelstein, B., Pomper, M.G.  Imaging bacterial infection in live animals with radiolabeled FIAU. Proc. Natl. Acad. Sci. USA 102:1145-51150, 2005.  Pub Med Reference

     


     
 
 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer